[go: up one dir, main page]

CL2017001472A1 - Composiciones y métodos que comprenden triglicéridos de cadena media para el tratamiento de la epilepsia. - Google Patents

Composiciones y métodos que comprenden triglicéridos de cadena media para el tratamiento de la epilepsia.

Info

Publication number
CL2017001472A1
CL2017001472A1 CL2017001472A CL2017001472A CL2017001472A1 CL 2017001472 A1 CL2017001472 A1 CL 2017001472A1 CL 2017001472 A CL2017001472 A CL 2017001472A CL 2017001472 A CL2017001472 A CL 2017001472A CL 2017001472 A1 CL2017001472 A1 CL 2017001472A1
Authority
CL
Chile
Prior art keywords
epilepsy
treatment
methods
aed
medium chain
Prior art date
Application number
CL2017001472A
Other languages
English (en)
Inventor
Yuanlong Pan
Brian Michael Zanghi
Jean Christophe Bouthegourd
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2017001472A1 publication Critical patent/CL2017001472A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/142Amino acids; Derivatives thereof
    • A23K20/147Polymeric derivatives, e.g. peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/158Fatty acids; Fats; Products containing oils or fats
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/20Inorganic substances, e.g. oligoelements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/42Dry feed
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/45Semi-moist feed
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pediatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Feed For Specific Animals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA COMPOSICIONES Y MÉTODOS PARA EL TRATAMIENTO DE LA EPILEPSIA EN UN ANIMAL. EN UNA MODALIDAD, UN RÉGIMEN DIETÉTICO ADECUADO PARA MEJORAR EL EFECTO DE UN FÁRMACO ANTIEPILÉPTICO (AED) EN UN ANIMAL PUEDE COMPRENDER UNA COMPOSICIÓN ALIMENTICIA QUE COMPRENDE UN TRIGLICÉRIDO DE CADENA MEDIA (MCT) Y EL AED, EN DONDE EL MCT ESTÁ PRESENTE EN LA COMPOSICIÓN ALIMENTICIA EN UNA CANTIDAD EFICAZ PARA MEJORAR EL EFECTO DEL AED CUANDO IA COMPOSICIÓN ALIMENTICIA Y EL AED SE ADMINISTRAN AL ANIMAL.</p>
CL2017001472A 2014-12-08 2017-06-08 Composiciones y métodos que comprenden triglicéridos de cadena media para el tratamiento de la epilepsia. CL2017001472A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462088797P 2014-12-08 2014-12-08

Publications (1)

Publication Number Publication Date
CL2017001472A1 true CL2017001472A1 (es) 2018-01-05

Family

ID=54979885

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001472A CL2017001472A1 (es) 2014-12-08 2017-06-08 Composiciones y métodos que comprenden triglicéridos de cadena media para el tratamiento de la epilepsia.

Country Status (18)

Country Link
US (1) US9789079B2 (es)
EP (1) EP3229790B1 (es)
JP (1) JP6923440B2 (es)
CN (1) CN106998748A (es)
AU (1) AU2015358958B2 (es)
CA (1) CA2968666C (es)
CL (1) CL2017001472A1 (es)
DK (1) DK3229790T3 (es)
ES (1) ES2761826T3 (es)
HR (1) HRP20192023T1 (es)
LT (1) LT3229790T (es)
MX (1) MX374942B (es)
NZ (1) NZ730880A (es)
PL (1) PL3229790T3 (es)
PT (1) PT3229790T (es)
RU (1) RU2712942C2 (es)
SI (1) SI3229790T1 (es)
WO (1) WO2016092459A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106462663A (zh) * 2014-04-08 2017-02-22 特种宠物食品公司 用于选择对宠物具有适口性作用和热量摄入减少作用的宠物食品的方法
US20170188548A1 (en) * 2014-05-26 2017-07-06 Specialites Pet Food Methods for selecting a petfood providing a satisfying feeding experience upon consumption by pets
US10973244B2 (en) 2017-11-17 2021-04-13 Hills Pet Nutrition, Inc. Compositions comprising omega-3 polyunsaturated and medium chain fatty acids
WO2020242437A1 (en) 2019-05-24 2020-12-03 Hill's Pet Nutrition, Inc. Pet food compositions comprising caprylic acid and docosahexaenoic acid and/or eicosapetaenoic acid for use in treating struvite urolithiasis
CN121174945A (zh) * 2023-04-01 2025-12-19 碗中动物健康公司 用于生产动物饲料的材料和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20020006959A1 (en) 2000-05-01 2002-01-17 Henderson Samuel T. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
SI1867644T1 (sl) * 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
ES2590259T3 (es) 2004-06-17 2016-11-21 Wisconsin Alumni Research Foundation Compuestos y procedimientos para el tratamiento de convulsiones y trastornos paroxísticos
WO2006105019A1 (en) 2005-03-25 2006-10-05 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
AU2006291588A1 (en) 2005-09-16 2007-03-22 Dsm Ip Assets B.V. Particulate lipid pharmaceutical composition
KR101634083B1 (ko) 2006-04-03 2016-06-28 액세라인크 나이와 관련된 기억 손상의 치료를 위한 케톤 생성 조성물의 용도
WO2009005519A1 (en) * 2007-06-29 2009-01-08 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
JP5931337B2 (ja) * 2007-10-04 2016-06-08 ネステク ソシエテ アノニム 認知機能を高める組成物及び方法
AU2009266869B2 (en) 2008-07-03 2016-07-07 Cerecin Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2014027023A1 (en) 2012-08-14 2014-02-20 Nestec S.A. Dietetic compositions for the treatment of malnutrition, neurological diseases and metabolic diseases
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus

Also Published As

Publication number Publication date
HRP20192023T1 (hr) 2020-02-07
EP3229790A1 (en) 2017-10-18
RU2017122796A (ru) 2019-01-10
MX2017007230A (es) 2017-10-16
PT3229790T (pt) 2020-01-22
JP6923440B2 (ja) 2021-08-18
WO2016092459A1 (en) 2016-06-16
AU2015358958B2 (en) 2020-10-01
MX374942B (es) 2025-03-06
AU2015358958A1 (en) 2017-04-27
CN106998748A (zh) 2017-08-01
US20160158183A1 (en) 2016-06-09
BR112017010381A2 (pt) 2017-12-19
DK3229790T3 (da) 2019-12-16
RU2712942C2 (ru) 2020-02-03
NZ730880A (en) 2022-07-01
JP2018504368A (ja) 2018-02-15
CA2968666C (en) 2022-08-30
ES2761826T3 (es) 2020-05-21
EP3229790B1 (en) 2019-10-16
CA2968666A1 (en) 2016-06-16
US9789079B2 (en) 2017-10-17
LT3229790T (lt) 2019-12-10
SI3229790T1 (sl) 2020-02-28
PL3229790T3 (pl) 2020-04-30
RU2017122796A3 (es) 2019-04-05

Similar Documents

Publication Publication Date Title
MX2021005187A (es) Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
MX2021014617A (es) Mitigantes quimicos en alimento para animales e ingredientes alimentarios.
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
CL2017001472A1 (es) Composiciones y métodos que comprenden triglicéridos de cadena media para el tratamiento de la epilepsia.
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
PH12017502375A1 (en) Method of treating inflammation using natural compounds and/or diet
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
MX2016012625A (es) Efecto de nutrientes lipofilicos en enfermedades de ojo diabetico.
CY1121880T1 (el) Συνθεση για την οφθαλμικη υγεια
MX2017004317A (es) Composiciones farmaceuticas y alimenticias para inducir la saciedad y prolongar la saciedad en sujetos que lo necesiten.
AR102085A1 (es) Composición nutricional para el entorno gastrointestinal para la provisión de un perfil metabólico y microbioma mejorados
MX2017005064A (es) Metodos para tratar afecciones oculares.
BR112017006779A2 (pt) composição farmacêutica oral de baixa dose seu processo de preparação e método de tratamento
MX2017007609A (es) Composicion y metodo para reducir o tratar la inflamacion oral.
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
MX2017003100A (es) Composiciones terapeuticas y nutricionales para trastornos gastrointestinales funcionales.
MX2017008668A (es) Composicion de alimentos y metodo de uso.
AR101673A1 (es) Composición para el tratamiento de neuropatías y del dolor neuropático
MX2020007171A (es) Mezcla de nutrientes para beneficios de salud en animales.
MX2018015588A (es) Pellets de alimento animal que incluyen un aditivo alimenticio, metodo para hacerlos y usarlos.
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor